

Previews

Green T_R Cells

Identification of the transcription factor Foxp3 as a “master regulator” of regulatory T (T_R) cells was a major discovery. A new study by Fontenot et al. (2005), reported in this issue of *Immunity*, provides novel insights into T_R cell biology by tracking their behavior in mice expressing a GFP-Foxp3 fusion-protein reporter.

All higher organisms harbor autoreactive T cells, which somehow survived central tolerance induction (i.e., negative selection during thymocyte differentiation) and have the potential of inducing organ-specific autoimmune disease (Ohashi, 2003). Therefore, in order for self-tolerance to be maintained, several peripheral tolerance mechanisms have evolved, including deletion, anergy, and active control of autoreactive T cells. (Van Parijs and Abbas, 1998).

Since the middle of the 1990s, a subset of T cells expressing the high affinity IL-2 receptor alpha chain (CD25) has emerged as a focus for immunologists interested in immunoregulation (Sakaguchi et al., 1995). CD4⁺CD25⁺ T_R cells are now known to play a central role in the maintenance of immunological homeostasis and self-tolerance in a number of autoimmunity, allergy, and infection models (for review see Sakaguchi [2004] and Shevach [2002]).

Nonetheless, a means of definitively identifying T_R cells has been elusive. CD25 expression is most commonly employed as a marker, and glucocorticoid-induced TNF receptor-related gene (GITR), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), neuropilin-1, or the integrin α_E (CD103) have also been used, but none of these molecules is really restricted to T_R cells. They are also expressed on T effector cell precursors upon activation, with the exception of neuropilin-1 and CD103, although the latter molecule can be induced in the presence of TGF- β . Recently, Foxp3, a member of the well-known and diverse forkhead transcription factor family, was identified as a master switch in T_R cell differentiation and function (Hori et al., 2003; Fontenot et al., 2003; Khattry et al., 2003). Because Foxp3 is not upregulated in recently activated CD4⁺CD25⁻ T cells, it seemed to be an excellent candidate for a specific marker of T_R cells.

By using mice harboring a GFP-Foxp3 fusion-protein reporter knockin allele, Fontenot and colleagues have now explored the role of Foxp3 in the hematopoietic system; in particular, the relationship between Foxp3 expression, cell-surface display of CD25, and T_R activity (Fontenot et al., 2005). In control studies, they first established the functional integrity of Foxp3 in reporter mice by demonstrating that T_R cells isolated from them had normal suppressive activity. Expression of the transcription factor fusion protein in the peripheral immune system was largely restricted to a small population of

TCR β^+ CD4⁺ T cells (which constituted 97% of the Foxp3^{gfp+} cells). Tiny populations of CD8⁺ T cells as well as CD4/CD8 double-positive and double-negative T cells that made Foxp3^{gfp} could also be discerned. Based on expression of Foxp3^{gfp} and CD25, CD4⁺ T cells could be divided into four subpopulations. Perhaps surprisingly to some, Foxp3 expression and T_R cell function were not well correlated with display of CD25. Notably, less than 50% of the Foxp3^{gfp+} lymphocytes isolated from the lungs exhibited high levels of CD25. It seems that CD25^{high}Foxp3^{gfp+} and CD25^{lo/neg}Foxp3^{gfp+} CD4⁺ T cells represent the pool of regulatory T cells, whereas the CD25^{high}Foxp3^{gfp-} population has an activated/effector phenotype with no regulatory potential (at least under the conditions analyzed in this study).

Compatible with a breakdown in peripheral self-tolerance, mice with a deficiency in Foxp3 show a rapid, fatal lymphoproliferative autoimmune syndrome at 3–4 weeks of age. Given that Foxp3-deficient mice display a much more severe autoimmune phenotype than do mice depleted of CD25⁺ cells, there has been speculation that Foxp3 might have an additional as-yet-uncharacterized role. However, Fontenot et al. (2005) made several arguments against this notion. First, this transcription factor was not expressed in any non-T cell populations, as was clearly evident from examining expression of the Foxp3-GFP-reporter in lymphocyte-deficient RAG^{o/o} mice. Second, a T cell-specific ablation of Foxp3 was sufficient to induce the full lymphoproliferative autoimmune syndrome observed in standard Foxp3-deficient mice. Third, a lack of Foxp3 did not influence the effector responses by T cells from Foxp3/RAG double-deficient T cell receptor transgenic mice. This finding argues against any cell-intrinsic function for Foxp3 in effector T cells, suggesting an exclusive role in regulatory T cells.

Most striking, and in contrast to previous assumptions (Stock et al., 2004), “adaptive” Foxp3-expressing T_R cells were not induced (as a form of feedback regulation) during the course of an acute immune response. There was no induction of this transcription factor after 7 days of in vitro culture in the presence of antigen and no de novo generation of Foxp3^{gfp+} cells in the course of an acute pathogen-driven immune response. Whether the system used by Fontenot et al. (2005) was sufficient to rule out any extrathymic induction of T_R cells remains in question, particularly in light of recent reports of the conversion of naive T cells into T_R cells in vivo (Liang et al., 2005; Apostolou and von Boehmer, 2004).

In another interesting, though still somewhat preliminary, set of experiments, the important question of T_R cell differentiation in the thymus was addressed. Expression of Foxp3 was largely restricted to CD4 single-positive thymocytes; however, minor populations of CD8 single-positive, double-positive, and double-negative thymocytes were also detectable. Foxp3 expression was strictly dependent on TCR/MHC molecule in-

teraction. Surprisingly, and consistent with the data from the periphery, a fraction of the $\text{Foxp3}^{\text{gfp}+}$ cells represented CD8^+ thymocytes dependent on expression of MHC class I molecules.

Overall, this study has established the validity of Foxp3 as a specific marker for regulatory T cells and has reported a novel mouse line of tremendous potential value in studies on immunoregulation. It has also raised some intriguing questions. Can the newly discovered $\text{CD8}^+\text{Foxp3}^{\text{gfp}+}$ T cells exert regulatory function comparable with that of $\text{CD4}^+\text{CD25}^+$ T_{R} cells? If so, in what context(s) do they emerge as important control elements? $\text{Foxp3}^{\text{gfp}+}$ T_{R} cells isolated from diverse sites showed some striking phenotypic differences; for example, peripheral organs were enriched in the $\text{CD25}^{\text{lo/neg}}\text{Foxp3}^{\text{gfp}+}$ population, which had an activated phenotype and included proliferating cells. Might these cells be the key to self-tolerance within tissues? Unlike $\text{CD4}^+\text{CD25}^+$ T_{R} cells, other immune cells with regulatory potential, including NKT cells and Tr1 cells, express no or low levels of Foxp3; thus, it is unlikely that this transcription factor and the gene-expression program it specifies is the only means of establishing tolerance dominantly. What is the master regulator of these cell-types and when do they come into play?

The powerful *in vivo* model introduced by Fontenot *et al.* (2005) opens the door for new insights into T_{R} cell biology. There is sure to be an onslaught of studies on antigen-specific systems, as well as adaptations to a diversity of pathological situations, including autoimmunity, chronic infection, transplantation, and tumorigenesis.

**Markus Feuerer, Christophe Benoist,
and Diane Mathis**
Section on Immunology and Immunogenetics
Joslin Diabetes Center
Department of Medicine
Brigham and Women's Hospital
Harvard Medical School
One Joslin Place
Boston, Massachusetts 02215

Selected Reading

- Apostolou, I., and von Boehmer, H. (2004). *J. Exp. Med.* 199, 1401–1408.
- Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. (2003). *Nat. Immunol.* 4, 330–336.
- Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and Rudensky, A.Y. (2005). *Immunity* 22, this issue, 329–341.
- Hori, S., Nomura, T., and Sakaguchi, S. (2003). *Science* 299, 1057–1061.
- Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. (2003). *Nat. Immunol.* 4, 337–342.
- Liang, S., Alard, P., Zhao, Y., Parnell, S., Clark, S.L., and Kosiewicz, M.M. (2005). *J. Exp. Med.* 201, 127–137.
- Ohashi, P.S. (2003). *Curr. Opin. Immunol.* 15, 668–676.
- Sakaguchi, S. (2004). *Annu. Rev. Immunol.* 22, 531–562.
- Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. (1995). *J. Immunol.* 155, 1151–1164.
- Shevach, E.M. (2002). *Nat. Rev. Immunol.* 2, 389–400.
- Stock, P., Akbari, O., Berry, G., Freeman, G.J., DeKruyff, R.H., and Umetsu, D.T. (2004). *Nat. Immunol.* 5, 1149–1156.
- Van Parijs, L., and Abbas, A.K. (1998). *Science* 280, 243–248.